News

Reuters1y
US FDA approves Ionis-AstraZeneca's nerve disease drug
The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease.
MedPage Today1y
FDA Approves New Agent for Nerve Pain From Rare Inherited Disease
Eplontersen (Wainua) was approved by the FDA to treat polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (ATTR) in adults, Ionis Pharmaceuticals and AstraZeneca announced ...
STAT1y
FDA approves AstraZeneca, Ionis treatment for rare nerve disease
The drug is a monthly injection for a genetic disorder called ATTR-PN, which affects about 30,000 people around the world and can be fatal if left untreated.
AOL1y
US FDA approves Ionis-AstraZeneca's nerve disease drug - AOL
The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease. The drug ...